Summary
Regeneron Pharmaceuticals, Inc. reported a strong first quarter for 2018, with net income soaring to $478.0 million, or $4.16 per diluted share, a significant increase from $248.9 million, or $2.16 per diluted share, in the prior year's first quarter. This growth was driven by a 14.6% increase in total revenues, reaching $1.51 billion, largely propelled by robust net product sales of EYLEA in the United States, which grew by 15.2% to $984.0 million. Collaboration revenues also saw a healthy increase, particularly from Bayer, which grew by 28.3% to $247.9 million, though Sanofi collaboration revenue saw a slight decrease. Key operational highlights include continued strong performance in clinical development pipelines, with significant progress noted for Dupixent, Cemiplimab, and EYLEA. The company also adopted new accounting standards (ASC 606) which impacted revenue recognition timing from collaboration agreements, resulting in a reclassification of revenue and a reduction in retained earnings. Despite ongoing legal proceedings related to patent infringements, particularly concerning Praluent and Dupixent, the company appears financially sound, with a substantial increase in cash and cash equivalents and a solid balance sheet. Investors can look forward to continued pipeline advancements and product commercialization efforts.
Financial Highlights
45 data points| Revenue | $1.51B |
| Cost of Revenue | $69.24M |
| Gross Profit | $1.44B |
| R&D Expenses | $498.60M |
| SG&A Expenses | $330.80M |
| Operating Expenses | $944.30M |
| Operating Income | $567.20M |
| Interest Expense | $6.40M |
| Net Income | $478.00M |
| EPS (Basic) | $4.44 |
| EPS (Diluted) | $4.16 |
| Shares Outstanding (Basic) | 107.60M |
| Shares Outstanding (Diluted) | 114.90M |
Key Highlights
- 1Net income more than doubled year-over-year, reaching $478.0 million ($4.16/share) in Q1 2018, up from $248.9 million ($2.16/share) in Q1 2017.
- 2Total revenues increased by 14.6% to $1.51 billion, driven by strong EYLEA sales in the US and increased collaboration revenue from Bayer.
- 3EYLEA net sales in the U.S. increased by 15.2% to $984.0 million, demonstrating continued market strength.
- 4Sanofi collaboration revenue decreased by 9.9% to $189.5 million, primarily due to the end of a discovery agreement and lower reimbursement for Dupixent development.
- 5Bayer collaboration revenue increased significantly by 28.3% to $247.9 million, indicating positive momentum in the EYLEA partnership outside the U.S.
- 6The company adopted ASC 606, resulting in a $143.4 million reduction in retained earnings and adjustments to deferred revenue recognition for collaboration agreements.
- 7Cash and cash equivalents increased by 25.4% to $1.02 billion, bolstering the company's liquidity position.